Gillett Health Q&A EP.3 | The Gillett Health Podcast #62

About this video

This listener Q&A ranges across hair-loss drugs, supplements, and GLP-1 risk debates. Gillett and O’Hara work through a question about dutasteride side effects by emphasizing lab work and total androgen status rather than assuming the drug is the cause, and they explain their reasoning for preferring moderate, sustainable approaches over aggressive dosing of long-acting medications. They debunk red yeast rice as effectively an unstandardized statin with extra compounds and added liver-injury reports. Toward the end they address GLP-1 safety fears, arguing the thyroid-cancer evidence is mixed and weak, and that risk judgments should weigh a patient’s baseline metabolic risk rather than relying on alarming case reports.

Key takeaways

• The hosts advise investigating labs and overall androgen status before blaming a hair-loss drug for sexual side effects
• They argue long-acting drugs deserve extra caution because side effects, if they occur, linger
• Red yeast rice is framed as an unregulated statin of uncertain composition rather than a gentler alternative
• They characterize the GLP-1 thyroid-cancer signal as conflicting and weak, not settled
• Risk-benefit thinking is presented as relative to each person’s starting metabolic risk

Episode details: published February 26, 2024 · 667 views · 41:09 long. Summary written by Self Growth Videos from the episode itself. The hormone, metabolic and peptide concepts described are Dr. Kyle Gillett’s, presented for education — not medical advice. Consult a qualified professional before changing your own health practices. Disclosure: Gillett Health is a clinical practice that treats these conditions.

← Previous: GLP1 Update | The Gillett Health Podcast #59 · Next: The Longevity Clinic Movement? →

All Dr. Kyle Gillett videos · Dr. Kyle Gillett profile · Gillett Health (official site)